BATS:ARKG ARK Genomic Revolution ETF (ARKG) Price, Holdings, & News $22.66 -0.95 (-4.00%) Closing price 05/2/2025 03:59 PM EasternExtended Trading$22.64 -0.02 (-0.09%) As of 05/2/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesHoldingsOwnershipRatingsBuy This Stock About ARK Genomic Revolution ETF (BATS:ARKG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ARKG alerts:Sign Up Key Stats Today's Range$24.20▼$25.2450-Day Range$18.27▼$25.6352-Week Range$17.51▼$31.16Volume4.90 million shsAverage Volume2.73 million shsMarket Capitalization$1.03 billionAssets Under Management$984.81 millionDividend YieldN/ANet Expense Ratio0.75%Aggregate RatingModerate Buy ETF OverviewThe ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.Read More… ARK Genomic Revolution ETF ExpensesTypeARKGTheme ETFsEquity ETFsBATS ETFsAll ETFsManagement Fee0.75%0.57%0.57%0.58%0.53%Other Expenses0.00%0.57%0.48%0.44%0.52%Total Expense0.75%0.73%0.72%0.69%0.71%Fee Waiver0.00%-0.71%-0.49%-0.34%-0.54%Net Expense0.75%0.60%0.63%0.65%0.60% Receive ARKG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARK Genomic Revolution ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address ARKG ETF News HeadlinesBMO ARK Genomic Revolution ETF Series (ARKG)May 1 at 9:55 PM | uk.investing.comBMO Announces the Termination of Certain BMO Mutual FundsApril 17, 2025 | finance.yahoo.comThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?May 4, 2025 | Timothy Sykes (Ad)Market sell-off shakes ETF issuers as Ark Invest gets hit the hardestMarch 18, 2025 | msn.com908 Devices Makes Key Divestiture (Rating Upgrade)March 6, 2025 | seekingalpha.comHC Wainwright & Co. Initiates Coverage of Intellia Therapeutics (NTLA) with Buy RecommendationMarch 5, 2025 | msn.comSee More Headlines ARKG ETF - Frequently Asked Questions How have ARKG shares performed this year? ARK Genomic Revolution ETF's stock was trading at $23.5450 at the start of the year. Since then, ARKG stock has decreased by 3.7% and is now trading at $22.6650. View the best growth stocks for 2025 here. Who are ARK Genomic Revolution ETF's major shareholders? ARK Genomic Revolution ETF's top institutional investors include IMC Chicago LLC, SG Americas Securities LLC (0.32%), Cambridge Investment Research Advisors Inc. (0.21%) and Envestnet Asset Management Inc. (0.15%). How do I buy shares of ARK Genomic Revolution ETF? Shares of ARKG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ARK Genomic Revolution ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that ARK Genomic Revolution ETF investors own include Invesco QQQ (QQQ), ARK Innovation ETF (ARKK), Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), AbbVie (ABBV) and PayPal (PYPL). Fund Details IssuerARK Fund NameARK Genomic Revolution ETF Tax ClassificationRegulated Investment Company Stock ExchangeBATSCurrent SymbolBATS:ARKG Inception Date10/31/2014 Fund ManagerCatherine Wood WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkN/A CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings34 Fund Statistics Assets Under Management$984.81 million Average Daily Volume$3.12 million Discount/Premium0.01% Administrator, Advisor and Custodian AdministratorThe Bank of New York Mellon Corporation AdvisorARK Investment Management LLC CustodianThe Bank of New York Mellon Corporation DistributorForeside Fund Services, LLC Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerJane Street Options OptionableOptionable Options Volume3,929 Put Options743 Call Options3,186 Miscellaneous Outstanding Shares45,450,000Beta1.80 Creation Unit50,000 Creation Fee$500.00 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Top 10 ARKG HoldingsTwist Bioscience (NASDAQ:TWST)Holding Weight: 9.03%CRISPR Therapeutics (NASDAQ:CRSP)Holding Weight: 8.23%Recursion Pharmaceuticals (NASDAQ:RXRX)Holding Weight: 6.98%Tempus AI (NASDAQ:TEM)Holding Weight: 6.97%Guardant Health (NASDAQ:GH)Holding Weight: 6.53%Natera (NASDAQ:NTRA)Holding Weight: 6.27%Adaptive Biotechnologies (NASDAQ:ADPT)Holding Weight: 5.94%Schrödinger (NASDAQ:SDGR)Holding Weight: 5.92%CareDx (NASDAQ:CDNA)Holding Weight: 4.38%Veracyte (NASDAQ:VCYT)Holding Weight: 4.04%Full Holdings DetailsARKG Sector ExposureARKG Industry Exposure This page (BATS:ARKG) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARK Genomic Revolution ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share ARK Genomic Revolution ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
